Allopurinol vs Febuxostat: Which Urate-Lowering Medication Is Right for You?

For people diagnosed with gout, understanding your medication options is one of the most important steps in managing this condition. Two of the most commonly prescribed urate-lowering therapies (ULT) are allopurinol and febuxostat (commonly known by the brand name Uloric). Both medications work by reducing uric acid production in the body, but they have different characteristics, benefits, and considerations.

This guide breaks down everything you need to know about these two medications to have an informed conversation with your healthcare provider.

Understanding How These Medications Work

Both allopurinol and febuxostat belong to a class of drugs called xanthine oxidase inhibitors (XOIs). They work by blocking an enzyme called xanthine oxidase, which is responsible for converting purines into uric acid. By inhibiting this process, both medications help lower the amount of uric acid circulating in your blood, which can reduce the risk of painful gout flares and prevent complications like tophi and kidney damage.

However, they differ in their potency, dosing, and how they are metabolized by the body.

Allopurinol: The First-Line Standard

Allopurinol has been the gold standard for urate-lowering therapy for decades. It is typically recommended as the first-line treatment by the American College of Rheumatology (ACR) guidelines due to its well-established safety profile and cost-effectiveness.

How Allopurinol Works

Allopurinol is a structural analog of hypoxanthine, a natural purine. It inhibits both the active and inactive forms of xanthine oxidase. Once absorbed, it is converted to oxypurinol, which is the active metabolite responsible for the drug’s urate-lowering effects.

Dosing and Titration

One of the key aspects of allopurinol therapy is proper dose titration. Starting with a low dose (typically 100 mg daily) and gradually increasing every 2-4 weeks helps minimize the risk of triggering a gout flare during the initiation phase. The maximum approved dose is 800 mg daily, but most patients achieve target uric acid levels at doses between 200-300 mg daily.

For patients with chronic kidney disease (CKD), dosing requires special attention. The starting dose should be no more than 100 mg daily 50 mg for those with severe CKD), with careful monitoring and slower titration.

Side Effects and Considerations

The most common side effects include skin rash, which can occasionally be severe (Stevens-Johnson syndrome in rare cases), and gastrointestinal symptoms like nausea. Allopurinol requires dose adjustment in patients with renal impairment.

A small percentage of patients carry the HLA-B*5801 allele, which is associated with an increased risk of severe cutaneous adverse reactions. This allele is more common in certain ethnic groups, including those of Han Chinese, Thai, and Korean descent.

Febuxostat: A More Potent Alternative

Febuxostat (brand name Uloric) was approved by the Food and Drug Administration (FDA) in 2009 as an alternative to allopurinol. It offers greater potency in reducing serum uric acid levels.

How Febuxostat Works

Febuxostat is a non-purine selective xanthine oxidase inhibitor. It selectively inhibits when it exists in different forms xanthine oxidase.

Dosing and Administration

Febuxostat is available in fixed doses of 40 mg and 80 mg daily, offering more predictable dosing compared to allopurinol. The 40 mg starting dose may be sufficient for many patients, but the 80 mg dose is available for those who need stronger urate-lowering. No dose adjustment is required for patients with mild to moderate renal impairment.

Cardiovascular Considerations

A major consideration with febuxostat is its potential cardiovascular risk. The CARES trial (2018) found a comparable risk of cardiovascular death with febuxostat versus allopurinol, though some studies have suggested a possible increased risk of cardiac events with febuxostat in certain high-risk patients. The FDA has issued a warning about this potential risk, and patients with a history of cardiovascular disease should discuss this with their healthcare provider.

Side Effects

Common side effects include liver function abnormalities, nausea, joint pain, and rash. Most side effects are mild and resolve with continued use.

Comparing Effectiveness: What Does the Research Say?

Recent meta-analyses have provided valuable insights into the comparative effectiveness of these two medications.

According to a network meta-analysis published in 2025, febuxostat at 120 mg demonstrated greater reduction in serum uric acid levels compared to allopurinol . However, allopurinol at 200-300 mg was found to be the best choice for reducing gout flares.

Another meta-analysis (2025) found that febuxostat significantly increased the number of patients achieving target serum uric acid levels of 6.0 mg/dL or less, particularly at doses above 80 mg daily. The study concluded that febuxostat has a favorable safety profile, though more high-quality studies are needed.

Key Differences at a Glance

Characteristic	Allopurinol	Febuxostat
First-line recommendation	Yes, preferred	Second-line option
Starting dose flexibility	Requires titration	Fixed 40 mg or 80 mg
Renal dose adjustment	Required	Not required
Cardiovascular warnings	No specific warnings	FDA black box warning (warnings to ensure both patients and healthcare providers are fully aware of critical safety hazards)
Cost	Generally lower	Generally higher
Maximum dose	800 mg daily	120 mg daily

Making the Right Choice for You

The choice between allopurinol and febuxostat depends on several individual factors:

Consider allopurinol if:
– You have mild to moderate gout
– Cost is a significant consideration
– You have normal kidney function or are willing to have doses carefully adjusted
– You want the most established safety profile

Consider febuxostat if:
– You have not achieved target uric acid levels with allopurinol despite adequate dosing
– You have chronic kidney disease (stages 3-4)
– You need more potent urate-lowering
– You have not tolerated allopurinol

Starting Either Medication: What to Expect

Regardless of which medication you decide to take, starting urate-lowering therapy requires patience. During the first few months, you may actually experience more gout flares as uric acid crystals dissolve in your joints. This is normal and does not mean the medication is not working.

Your doctor may recommend:
– Starting with a low dose and increasing gradually
– To take colchicine or an NSAID prophylactically during the first 3-6 months
– Staying well hydrated
– Avoiding known dietary triggers

Regular blood tests to monitor your uric acid levels will help determine if your dose needs adjustment.

The Bottom Line

Both allopurinol and febuxostat are effective urate-lowering medications that can help you achieve the ACR-recommended target serum uric acid level of less than 6.0 mg/dL (or below 5.0 mg/dL in patients with tophi).

Allopurinol remains the recommended first-line option due to its established safety profile and lower cost. Febuxostat is a valuable alternative for patients who do not respond adequately to allopurinol or who have certain contraindications.

The most important steps are to work closely with your healthcare provider, have realistic expectations about the treatment timeline, and commit to long-term medication adherence. With proper treatment, most people with gout can achieve significant improvement in their symptoms and quality of life.

Frequently Asked Questions

Can I switch from allopurinol to febuxostat if one is not working?

Yes. If you have not achieved target uric acid levels with an adequate dose of allopurinol (typically 300–400 mg daily), or if you experience intolerable side effects, your doctor may consider switching you to febuxostat. Febuxostat is generally more potent and may be better tolerated by some patients.

Do I need to take urate-lowering medication forever?

For most people with gout, urate-lowering therapy is a long-term commitment. Stopping medication typically leads to a rise in uric acid levels and return of symptoms. Your doctor will monitor your progress and may consider dose reduction only after you have maintained target uric acid levels for an extended period with no flares.

Can I take urate-lowering medication during a gout flare?

It is generally recommended to continue your urate-lowering medication during a flare unless your doctor advises otherwise. Stopping and starting medication can cause fluctuations in uric acid levels that may actually prolong or worsen flares. Consistent dosing is key to managing uric acid effectively.

Are there any food restrictions when taking allopurinol or febuxostat?

Unlike earlier concerns, there are no specific dietary restrictions mandated by either medication. However, maintaining a balanced diet and limiting very high-purine foods can complement your medication therapy. Most patients can eat a varied diet with appropriate portion sizes rather than strictly avoiding individual foods.

Frequently Asked Questions

Is febuxostat safer than allopurinol for the heart?

The FAST study (2020) found that febuxostat was not associated with a higher risk of cardiovascular death compared to allopurinol, which reversed earlier concerns from the CARES trial. According to this newer study, the two medications appear to have similar cardiovascular safety profiles for most patients. Your doctor will consider your specific cardiovascular risk factors when choosing between them.

Can I switch from allopurinol to febuxostat?

Yes, switching is possible and sometimes necessary — for example, if you experience a rash on allopurinol or cannot reach your uric acid target. The switch should be done under medical supervision, and your doctor will typically overlap the medications briefly or adjust dosing to prevent a flare during the transition.

Why does allopurinol sometimes cause flares when starting?

When uric acid levels drop rapidly, existing crystal deposits in your joints can partially dissolve and shed, triggering an immune response. This is called a mobilization flare. It is actually a sign the medication is working. Doctors often prescribe colchicine or an NSAID in addition to allopurinol for the first 3-6 months to prevent these flares.

How long does it take for these medications to work?

Both allopurinol and febuxostat begin lowering uric acid within days, but it takes months for crystal deposits to dissolve completely. Most patients reach their uric acid target within 2-6 months at the right dose. Flare prevention during this period is critical — the lack of flares does not mean you should stop the medication.

Reviewed by the GoutSavvy Editorial Team